权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Practical Implementation of an Ultra-rapid FLASH Radiation Therapy Linac Beamline

超快速 FLASH 放射治疗直线加速器光束线的实际实施

基本信息

批准号：
9909501
负责人：
Vinod Bharadwaj
金额：
$ 99.99万
依托单位：
TIBARAY, INC.
依托单位国家：
美国
项目类别：
财政年份：
2017
资助国家：
美国
起止时间：
2017-03-17 至 2021-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9909501
关键词：
3-Dimensional Abate Address Biology Cause of Death Clinical Collimator Complex Contracts Devices Dose Dose-Rate Electron Beam Electrons Epidemic Failure Freezing Funding Generations Goals Guns Hand Image Infrastructure Legal patent Magnetism Maintenance Measures Mechanics Medical Methods Mission Monitor Motion Organ Output Performance Phase Photons Physiologic pulse Physiological Plant Leaves Production Radiation Radiation Dose Unit Radiation Oncology Radiation therapy Resolution Risk Roentgen Rays Scanning Scheme Science Secure Shapes Small Business Innovation Research Grant Source Specific qualifier value Speed Study models System Techniques Technology Testing Therapeutic Therapeutic Index Time Tissues Toxic effect Translating Universities Work base beamline cancer radiation therapy cancer therapy clinical translation commercialization cost cost effective cost effectiveness design improved innovation new technology next generation novel off-patent phase 1 designs preclinical study proton therapy prototype radiation delivery radio frequency side effect simulation treatment planning tumor

项目摘要

PROJECT SUMMARY/ABSTRACT The mission of TibaRay, Inc. is to develop and clinically translate next-generation radiation therapy technologies for the treatment of cancer, the single leading cause of death worldwide and increasing epidemically. A major advance in radiation therapy (RT) that has increased its curative potential and decreased side effects is the ability to sculpt radiation doses exquisitely in 3D to conform to tumors and spare surrounding healthy organs. This is achieved by delivering radiation beams to the tumor from multiple directions, each of which has an optimized spatial intensity distribution. However, the fastest treatment times are still minutes long, limited by both beam intensities in electron linacs and the mechanical systems that are used to direct and shape the beams. Recently, ultra-fast (<1s) high dose rate (300X) FLASH-RT has proven in pre-clinical studies to have high therapeutic index. But there is no existing technology to enable this therapy in the clinical, photon-based setting. To address these major shortcomings of current state-of-the-art radiation delivery systems, TibaRay has proposed a radical new design for RT systems, Pluridirectional High-energy Agile Scanning Electronic Radiotherapy (PHASER). It is based on patented, novel technologies to produce intensity-modulated therapeutic energy x-ray beams from multiple directions using no mechanical systems to direct (i.e. no rotating gantry) or shape the treatment beams (i.e. no mulit-leaf collimator). This is achieved by using an array of novel electron linacs each of which uses a magnetic electron beam scanning scheme paired with an extended bremsstrahlung target and multi-channel collimator array system referred to as Scanning Pencil-array-collimated High Speed Intensity-modulated X-ray source (SPHINX). Each of the novel linacs used in PHASER are far more efficient and will generate more beam than conventional medical linacs. In the full PHASER design, it is estimated that the treatment time can be reduced to <1s, effectively freezing physiological motion. The novel accelerator technology uses much simpler manufacturing techniques and production costs for PHASER are projected to be about the same as current state-of-the-art systems and maintenance/downtime costs should be lower. Initial proof of principle for the subsystems needed for PHASER have been demonstrated and design simulations have been performed in Phase 1. In Phase II, TibaRay, in partnership with the Stanford University Department of Radiation Oncology will optimize, build and test at first a single complete beam line with full maximum power. Then we will build and test a two-beam PHASER prototype to demonstrate the full rapid RF switching capability. These tests will be used to de-risk the primary working components of the system and will enable swift progress towards commercialization and clinical translation. Our novel technology will help fill a tremendous worldwide need for high-quality, cost-effective radiation therapy for cancer.

项目总结/文摘